Thomas W Carver1, Nathan W Kugler, Janelle Juul, William J Peppard, Karin Madsen Drescher, Lewis B Somberg, Aniko Szabo, Ziyan Yin, Jasmeet S Paul. 1. From the Division of Trauma and Acute Care Surgery, Department of Surgery (T.W.C.), Division of Trauma and Acute Care Surgery, Department of Surgery (N.W.K.), Division of Critical Care Pharmacy, Department of Pharmacy (J.J.), Division of Trauma and Acute Care Surgery, Department of Surgery (W.J.P.), Division of Regional Anesthesia and Acute Pain Management, Department of Anesthesia (K.M.D.), Division of Trauma and Acute Care Surgery, Department of Surgery (L.B.S.), Division of Biostatistics (A.S., Z.Y.), and Division of General Surgery, Department of Surgery (J.S.P.), Medical College of Wisconsin, Milwaukee, Wisconsin.
Abstract
BACKGROUND:Rib fractures occur in up to 40% of trauma patients and are associated with increased mortality. Opiate-based pain regimens remain the cornerstone of rib fracture management; however, concerns around opioids have fostered interest in alternative analgesics. Ketamine is currently being used in lieu of opioids, but little evidence exists supporting its use within the trauma population. METHODS: A prospective, randomized, double-blind placebo-controlled trial of adult patients with three or more rib fractures admitted to a Level I trauma center was conducted. Exclusion criteria included age older than 64 years, Glasgow Coma Scale score less than 13, and chronic opiate use. The experimental arm received low-dose ketamine (LDK) at 2.5 μg·kg·min while the placebo cohort received an equivalent rate of 0.9% normal saline. All infusions were continued for 48 hours. The primary outcome was reduction in numeric pain score (NPS) during the first 24 hours. Secondary outcomes studied included oral morphine equivalent (OME) utilization, length of stay, epidural rates, pulmonary complications, and adverse events. RESULTS:Forty-five (49%) of 91 patients were randomized to the experimental arm. Both groups were similar in makeup. Overall, 74.7% were male, had a median age of 49 years, and an Injury Severity Score (ISS) of 14. Low-dose ketamine was not associated with a significant reduction in 24-hour NPS or OME totals. Subgroup analysis of 45 severely injured patients (ISS, >15) demonstrated that LDK was associated with a significant reduction in OME utilization during the first 24 hours (35.7 vs. 68, p = 0.03), 24 hours to 48 hours (64.2 vs. 96, p = 0.03), and overall (152.1 vs. 198, p = 0.048). No difference in other secondary outcomes or adverse events was noted. CONCLUSION: Low-dose ketamine failed to decrease NPS or OME within the overall cohort, but a decrease in OME was observed among patients with an ISS greater than 15. Confirmatory studies are necessary to determine if LDK is a useful adjunct among severely injured patients. LEVEL OF EVIDENCE: Therapeutic study, level II.
RCT Entities:
BACKGROUND: Rib fractures occur in up to 40% of traumapatients and are associated with increased mortality. Opiate-based pain regimens remain the cornerstone of rib fracture management; however, concerns around opioids have fostered interest in alternative analgesics. Ketamine is currently being used in lieu of opioids, but little evidence exists supporting its use within the trauma population. METHODS: A prospective, randomized, double-blind placebo-controlled trial of adult patients with three or more rib fractures admitted to a Level I trauma center was conducted. Exclusion criteria included age older than 64 years, Glasgow Coma Scale score less than 13, and chronic opiate use. The experimental arm received low-dose ketamine (LDK) at 2.5 μg·kg·min while the placebo cohort received an equivalent rate of 0.9% normal saline. All infusions were continued for 48 hours. The primary outcome was reduction in numeric pain score (NPS) during the first 24 hours. Secondary outcomes studied included oral morphine equivalent (OME) utilization, length of stay, epidural rates, pulmonary complications, and adverse events. RESULTS: Forty-five (49%) of 91 patients were randomized to the experimental arm. Both groups were similar in makeup. Overall, 74.7% were male, had a median age of 49 years, and an Injury Severity Score (ISS) of 14. Low-dose ketamine was not associated with a significant reduction in 24-hour NPS or OME totals. Subgroup analysis of 45 severely injured patients (ISS, >15) demonstrated that LDK was associated with a significant reduction in OME utilization during the first 24 hours (35.7 vs. 68, p = 0.03), 24 hours to 48 hours (64.2 vs. 96, p = 0.03), and overall (152.1 vs. 198, p = 0.048). No difference in other secondary outcomes or adverse events was noted. CONCLUSION: Low-dose ketamine failed to decrease NPS or OME within the overall cohort, but a decrease in OME was observed among patients with an ISS greater than 15. Confirmatory studies are necessary to determine if LDK is a useful adjunct among severely injured patients. LEVEL OF EVIDENCE: Therapeutic study, level II.
Authors: John A Harvin; Van Thi Thanh Truong; Charles E Green; LaDonna Allen; Jason Murry; John J Radosevich; James N Bogert; Patrick B Murphy; Brandy B Padilla-Jones; Ben L Zarzaur; John R Taylor; Kevin W Sexton; Cassandra Decker; Thomas J Schroeppel; Charles E Wade; Lillian S Kao Journal: J Trauma Acute Care Surg Date: 2020-06 Impact factor: 3.697
Authors: Sharven Taghavi; Ayman Ali; Erik Green; Kyle Schmitt; Olan Jackson-Weaver; Danielle Tatum; Charles Harris; Chrissy Guidry; Patrick McGrew; Rebecca Schroll; Jay Kolls; Juan Duchesne Journal: Surgery Date: 2020-12-19 Impact factor: 3.982
Authors: Christine M Groth; Christopher A Droege; Kathryn A Connor; Kimberly Kaukeinen; Nicole M Acquisto; Sai Ho J Chui; Michaelia D Cucci; Deepali Dixit; Alexander H Flannery; Kyle A Gustafson; Nina E Glass; Helen Horng; Mojdeh S Heavner; Justin Kinney; Rachel M Kruer; William J Peppard; Preeyaporn Sarangarm; Andrea Sikora; Velliyur Viswesh; Brian L Erstad Journal: Crit Care Explor Date: 2022-02-10
Authors: Thaddeus J Puzio; James Klugh; Michael W Wandling; Charles Green; Julius Balogh; Samuel J Prater; Christopher T Stephens; Paulina B Sergot; Charles E Wade; Lillian S Kao; John A Harvin Journal: Trials Date: 2022-07-27 Impact factor: 2.728